


Supplementary material

This file contains

- Figures 1-11
- Tables 1-14



PRISMA 2009 Flow Diagram



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.

Figure 1. PRISMA flow chart. In adherence with the PRISMA guidelines,¹ two independent researchers (A.J. and W.M.) conducted the literature search and extracted the data. Their independent searches were compared by S.W.

Variability ratio including the second period of the crossover trials

The same meta-analysis with the second period of the crossover trial included shows that the same direction of the effect observed in the main analysis.




Figure 2. Variability ratio (VR) stratified by disorder. The forest plot shows the VR together with its 95% confidence interval (CI) for active vs sham by disorder. The direction of results did not change when including the second period of each crossover trial.




Figure 3. Risk of bias assessment. In adherence with the PRISMA guidelines,¹ two independent researchers (A.J. and W.M.) conducted the literature search and screened the articles, eliminated duplicates, decided whether the article met the inclusion criteria, and extracted all relevant data from the final articles. Their independent searches were compared by S.W., discrepancies investigated, and resolved by discussion. The risk of bias of the included studies was assessed independently by S.W. and N.M. according to the Cochrane Handbook for Systematic Reviews of Interventions.² The bar chart was produced with the *dmatar* package³ in R. See also the following table with the risk of bias assessment for each of the included studies.

Cochrane Risk of Bias Assessment for all studies

| Studies | Random sequence generation | Allocation concealment | Selective reporting | Blinding (participants and personnel) | Blinding (outcome assessment) | Incomplete outcome data | Other sources of bias | Summary | Rating |
|------------------------------|----------------------------|------------------------|---------------------|---------------------------------------|-------------------------------|-------------------------|-----------------------|---------|--------|
| Anderson et al., 2007 | unclear | low | low | unclear | low | low | low | unclear | C |
| Avery et al., 2006 | low | unclear | low | low | low | low | high | high | A |
| Baeken et al., 2013 | low | unclear | low | low | low | low | high | high | A |
| Baeken et al., 2015 | low | unclear | low | unclear | unclear | low | high | high | A |
| Bais et al., 2014 | low | unclear | low | low | unclear | low | low | unclear | C |
| Barr et al., 2012 | low | unclear | low | unclear | unclear | low | low | unclear | C |
| Benadhira et al., 2017 | unclear | unclear | low | low | unclear | low | low | unclear | C |
| Berman et al., 2000 | unclear | unclear | low | low | low | high | low | high | A |
| Blumberger et al., 2012 | low | low | low | low | low | low | low | low | B |
| Blumberger et al., 2012a | unclear | unclear | low | low | low | low | low | unclear | C |
| Blumberger et al., 2016 | low | unclear | low | low | low | low | low | unclear | C |
| Boggio et al., 2008 | low | unclear | low | low | low | low | high | high | A |
| Bortolomasi et al., 2007 | unclear | unclear | low | low | low | high | high | high | A |
| Boutros et al., 2002 | low | unclear | low | low | low | low | high | high | A |
| Bretlau et al., 2008 | unclear | unclear | low | unclear | low | low | low | unclear | C |
| Brunelin et al., 2012 | unclear | unclear | low | low | low | low | low | unclear | C |
| Brunoni et al., 2013 | low | low | low | low | low | low | low | low | B |
| Brunoni et al., 2013a | low | low | low | low | low | low | low | low | B |
| Brunoni et al., 2014 | low | low | low | unclear | low | low | low | unclear | C |
| Brunoni et al., 2017 | low | unclear | low | low | low | low | high | high | A |
| Carpenter et al., 2017 | low | low | low | low | unclear | low | low | unclear | C |
| Carretero et al., 2009 | unclear | unclear | low | low | unclear | low | low | unclear | C |
| Dlabac-de Lange et al., 2015 | low | low | low | low | unclear | low | low | unclear | C |
| Dolberg et al., 2002 | unclear | unclear | low | unclear | unclear | low | high | high | A |
| Elbeh et al., 2016 | unclear | low | low | unclear | low | low | low | unclear | C |




Figure 4. Sensitivity analysis. We excluded all studies for which risk of bias was high and re-analyzed the data. The forest plot shows the VR together with its 95% confidence interval (CI) for active vs sham by disorder. The VR was not increased after active stimulation compared with sham, for neither of the diagnostic groups.




Figure 5. Brain stimulation methods and disorder. The frequency bar plot shows the number of studies that investigated which non-invasive brain stimulation method in which psychiatric population.

Additional plots for main analysis

VR by disorder by stimulation method

Major depressive disorder




Figure 6. Variability ratio (VR) by stimulation method in the depression studies. The forest plot shows the VR together with its 95% confidence interval (CI) for active vs sham by stimulation method. The variability was not increased after active stimulation compared with sham, with the exception for rTMS.

Schizophrenia spectrum disorder




Figure 7. Variability ratio (VR) by stimulation method in the schizophrenia studies. The forest plot shows the VR together with its 95% confidence interval (CI) for active vs sham by stimulation method. The variability was not increased after active stimulation compared with sham.

Obsessive-compulsive disorder




Figure 8. Variability ratio (VR) by stimulation method in the OCD studies. The forest plot shows the VR together with its 95% confidence interval (CI) for active vs sham by stimulation method. The variability was not increased after active stimulation compared with sham.

Bipolar disorder




Figure 9. Variability ratio (VR) by stimulation method in the bipolar disorder studies. The forest plot shows the VR together with its 95% confidence interval (CI) for active vs sham by stimulation method. The variability was not increased after active stimulation compared with sham.




Figure 10. Relationship of effect size and year of publication. The bubble plot shows the relationship between the standardized mean differences (SMD) and year of publication. Only studies in patients with a schizophrenia spectrum diagnosis showed a significant relationship between decreasing effect sizes and time.




Figure 11. Mean-variance relationship. The bubble plot shows a significant mean-variance relationship for studies in patients with schizophrenia. It was suggested that this may limit the variability ratio in its applicability to identify shifts in variances and would call for the use of the coefficient of variation ratio (CVR) instead.⁴ Yet, the CVR is scale-dependent and should only be used for outcome data on the ratio scale with a true zero.⁵

Table 1
Descriptives for TMS in depression studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|-----------------------------|-----------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Anderson et al., 2007 | RCT | MADRS | 13.00 | 48.00 | 26.70 | 3.60 | 15.00 | 9.70 | -11.70 | 8.08 |
| Avery et al., 2006 | RCT | HDRS 17 | 35.00 | 44.30 | 23.50 | 3.90 | 15.70 | 8.72 | -7.80 | 7.80 |
| Baeken et al., 2013 (1) | crossover | HDRS 17 | 9.00 | 51.78 | 26.33 | 8.15 | 19.63 | 8.35 | -6.70 | 7.42 |
| Baeken et al., 2015 (1) | crossover | HDRS | 9.00 | 50.78 | 25.44 | 6.79 | 17.89 | 6.79 | -7.55 | 6.10 |
| Benadhira et al., 2017 | RCT | HDRS 17 | 10.00 | 51.80 | 9.10 | 4.65 | 8.50 | 4.01 | -0.60 | 3.93 |
| Berman et al., 2000 | RCT | HDRS 25 | 10.00 | 45.20 | 37.10 | 9.20 | 23.10 | 14.89 | -14.00 | 11.70 |
| Blumberger et al., 2012 (1) | RCT | HDRS 17 | 22.00 | 48.90 | 26.00 | 3.30 | 19.60 | 5.60 | -6.40 | 4.50 |
| Blumberger et al., 2012 (2) | RCT | HDRS 17 | 26.00 | 58.00 | 25.10 | 3.80 | 15.30 | 6.70 | -9.80 | 5.38 |
| Blumberger et al., 2016 (2) | RCT | HDRS 17 | 40.00 | 46.50 | 26.00 | 3.40 | 19.60 | 7.78 | -6.40 | 7.00 |
| Blumberger et al., 2016 (1) | RCT | HDRS 17 | 40.00 | 46.40 | 24.10 | 3.20 | 17.30 | 7.88 | -6.80 | 7.20 |
| Bortolomasi et al., 2007 | RCT | HAMD 24 | 12.00 | NA | 25.17 | 7.80 | 11.33 | 9.00 | -13.84 | 7.63 |
| Boutros et al., 2002 | RCT | HDRS | 12.00 | 49.50 | 34.40 | 10.10 | 27.10 | 13.20 | -7.30 | 10.83 |
| Bretlau et al., 2008 | RCT | HDRS | 22.00 | 53.10 | 25.30 | 3.00 | 16.40 | 4.50 | -8.90 | 3.63 |
| Carpenter et al., 2017 | RCT | HDRS 24 | 47.00 | 45.60 | 31.30 | 5.50 | 16.20 | 11.06 | -15.10 | 9.60 |
| Carretero et al., 2009 | RCT | HDRS 17 | 14.00 | 47.50 | 19.40 | 5.40 | 15.60 | 3.80 | -3.80 | 4.38 |
| Fitzgerald et al., 2003 (1) | crossover | MADRS | 20.00 | 42.20 | 36.05 | 7.55 | 30.80 | 7.50 | -5.25 | 6.76 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|-----------------------------|-----------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Fitzgerald et al., 2006 | RCT | MADRS | 25.00 | 46.80 | 34.00 | 5.90 | 26.20 | 10.20 | -7.80 | 8.19 |
| Fitzgerald et al., 2012 (2) | RCT | HDRS 17 | 22.00 | 40.45 | 24.30 | 3.60 | 22.20 | 6.00 | -2.10 | 4.82 |
| Fitzgerald et al., 2012 (1) | RCT | HDRS 17 | 24.00 | 43.40 | 23.70 | 3.80 | 19.60 | 4.20 | -4.10 | 3.61 |
| Garcia-Toro et al., 2001 | RCT | HDRS 21 | 17.00 | 51.50 | 27.11 | 6.65 | 20.06 | 8.73 | -7.05 | 5.66 |
| Garcia-Toro et al., 2001a | RCT | HDRS 21 | 11.00 | 43.20 | 25.90 | 6.40 | 16.10 | 7.70 | -9.80 | 6.44 |
| George et al., 1997 (1) | crossover | HDRS 21 | 7.00 | 42.43 | 30.00 | 4.00 | 23.00 | 9.00 | -7.00 | 7.35 |
| George et al., 2000 (1) | RCT | HDRS 21 | 10.00 | 42.60 | 30.00 | 5.80 | 22.20 | 10.60 | -7.80 | 8.53 |
| George et al., 2000 (2) | RCT | HDRS 21 | 10.00 | 42.20 | 26.30 | 5.90 | 13.50 | 5.80 | -12.80 | 5.26 |
| George et al., 2010 | RCT | HDRS | 92.00 | 47.70 | 26.26 | 4.95 | 21.61 | 9.26 | -4.65 | 7.46 |
| Hausmann et al., 2004 | RCT | HDRS 21 | 25.00 | 46.28 | 32.30 | 5.90 | 17.60 | 9.00 | -14.70 | 7.25 |
| Holtzheimer et al., 2004 | RCT | HDRS 17 | 7.00 | 40.40 | 22.70 | 5.30 | 14.60 | 3.20 | -8.10 | 4.26 |
| Hoppner et al., 2003 (2) | RCT | HDRS 21 | 10.00 | 52.00 | 22.80 | 4.70 | 16.50 | 7.00 | -6.30 | 5.65 |
| Hoppner et al., 2003 (1) | RCT | HDRS 21 | 10.00 | 60.36 | 22.50 | 4.50 | 14.50 | 6.00 | -8.00 | 4.91 |
| Huang et al., 2012 | RCT | HDRS 17 | 28.00 | 32.77 | 22.71 | 2.27 | 15.36 | 1.73 | -7.35 | 1.86 |
| Januel et al., 2006 | RCT | HDRS 17 | 11.00 | 38.64 | 21.73 | 3.52 | 9.90 | 5.95 | -11.83 | 4.78 |
| Kang et al., 2016 | RCT | HDRS 17 | 12.00 | 42.80 | 24.10 | 6.40 | 10.10 | 3.80 | -14.00 | 5.14 |
| Klein et al., 1999 | RCT | HDRS 17 | 36.00 | 60.50 | 25.80 | 5.60 | 13.70 | 9.20 | -12.10 | 7.39 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|------------------------------------|--------|---------------|--------|-------|-------|--------|-------|--------|----------|-----------|
| Koerselman et al., 2004 | RCT | HDRS 17 | 26.00 | 51.00 | 25.90 | 4.33 | 21.10 | 7.47 | -4.80 | 6.00 |
| Kreuzer et al., 2012 | RCT | HDRS modified | 21.00 | 45.30 | 21.43 | 5.30 | 8.74 | 6.10 | -12.69 | 5.17 |
| Krstic et al., 2014 | RCT | HDRS 24 | 11.00 | 50.70 | 30.09 | 3.53 | 16.73 | 5.71 | -13.36 | 4.59 |
| Leuchter et al., 2015 | RCT | HDRS 17 | 59.00 | 46.70 | 21.78 | 3.79 | 12.78 | 5.90 | -9.00 | 4.75 |
| Manes et al., 2001 | RCT | HDRS | 10.00 | 60.50 | 22.70 | 5.20 | 13.70 | 5.40 | -9.00 | 4.77 |
| Mantovani et al., 2013 | RCT | HDRS 24 | 12.00 | 40.20 | 31.90 | 6.50 | 25.30 | 9.80 | -6.60 | 7.90 |
| Mogg et al., 2008 | RCT | HDRS 17 | 29.00 | 55.00 | 20.50 | 4.40 | 16.00 | 8.24 | -4.50 | 6.64 |
| Moller et al., 2006 | RCT | HDRS 17 | 10.00 | 54.00 | 22.10 | 7.00 | 13.80 | 7.00 | -8.30 | 6.29 |
| Mosimann et al., 2004 | RCT | HDRS 21 | 15.00 | 60.00 | 28.50 | 4.60 | 23.30 | 7.20 | -5.20 | 5.79 |
| Nongpiur et al., 2011 | RCT | HDRS 21 | 18.00 | 33.28 | 29.00 | 5.97 | 8.56 | 4.68 | -20.44 | 4.92 |
| O'Reardon et al., 2007 | RCT | MADRS | 155.00 | 47.90 | 32.80 | 6.00 | 27.00 | 11.10 | -5.80 | 8.93 |
| Padberg et al., 1999 (1) | RCT | HDRS | 6.00 | 63.50 | 30.20 | 9.50 | 28.50 | 9.40 | -1.70 | 8.50 |
| Padberg et al., 1999 (2) | RCT | HDRS | 6.00 | 46.70 | 26.70 | 9.40 | 21.50 | 21.50 | -5.20 | 17.60 |
| Paillere-Martinot et al., 2010 (3) | RCT | MADRS | 7.00 | NA | 34.70 | 6.00 | 23.30 | 14.50 | -11.40 | 13.20 |
| Paillere-Martinot et al., 2010 (1) | RCT | MADRS | 18.00 | 48.19 | 32.00 | 7.78 | 17.30 | 11.82 | -14.70 | 8.90 |
| Paillere-Martinot et al., 2010 (2) | RCT | MADRS | 9.00 | NA | 34.00 | 8.50 | 13.70 | 15.37 | -20.30 | 12.80 |
| Pallanti et al., 2010 (1) | RCT | HDRS | 20.00 | 47.60 | 28.75 | 6.01 | 22.00 | 6.71 | -6.75 | 5.75 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|------------------------------|-----------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Pallanti et al., 2010 (2) | RCT | HDRS | 20.00 | 51.20 | 27.95 | 5.89 | 16.00 | 7.60 | -11.95 | 6.25 |
| Pascual-Leone et al., 1996 | crossover | HDRS 21 | 17.00 | 48.60 | 25.20 | 13.50 | 13.80 | 14.00 | -11.40 | 12.37 |
| Ray et al., 2011 | RCT | HDRS | 20.00 | 36.75 | 29.60 | 3.79 | 4.50 | 5.23 | -25.10 | 4.25 |
| Rossini et al., 2005 | RCT | HDRS 24 | 50.00 | 48.40 | 25.10 | 3.50 | 13.01 | 8.08 | -12.09 | 7.28 |
| Rumi et al., 2005 | RCT | HDRS 17 | 22.00 | 39.30 | 29.71 | 6.38 | 13.00 | 6.38 | -16.71 | 5.74 |
| Speer et al., 2014 (1) | RCT | HDRS 28 | 8.00 | 41.30 | 35.80 | 10.60 | 32.50 | 10.10 | -3.30 | 9.31 |
| Speer et al., 2014 (2) | RCT | HDRS 28 | 8.00 | 39.60 | 28.60 | 7.60 | 25.10 | 6.90 | -3.50 | 6.55 |
| Stern et al., 2007 (2) | RCT | HDRS 21 | 10.00 | 52.30 | 27.60 | 3.90 | 27.60 | 5.90 | 0.00 | 4.75 |
| Stern et al., 2007 (3) | RCT | HDRS 21 | 10.00 | 52.80 | 27.90 | 3.80 | 15.80 | 4.80 | -12.10 | 3.97 |
| Stern et al., 2007 (1) | RCT | HDRS 21 | 10.00 | 53.20 | 27.80 | 3.20 | 15.10 | 6.00 | -12.70 | 4.83 |
| Su et al., 2005 (1) | RCT | HDRS 21 | 10.00 | 43.60 | 23.20 | 7.50 | 9.80 | 7.10 | -13.40 | 6.57 |
| Su et al., 2005 (2) | RCT | HDRS 21 | 10.00 | 43.20 | 26.50 | 5.20 | 12.30 | 7.70 | -14.20 | 6.21 |
| Theleiteris et al., 2017 (1) | RCT | HDRS 17 | 26.00 | 39.10 | 30.60 | 3.20 | 15.60 | 3.70 | -15.00 | 3.13 |
| Theleiteris et al., 2017 (3) | RCT | HDRS 17 | 26.00 | 39.10 | 30.60 | 3.20 | 15.60 | 3.70 | -15.00 | 3.13 |
| Theleiteris et al., 2017 (2) | RCT | HDRS 17 | 26.00 | 38.90 | 29.70 | 4.60 | 13.10 | 4.50 | -16.60 | 4.09 |
| Theleiteris et al., 2017 (4) | RCT | HDRS 17 | 26.00 | 38.90 | 29.70 | 4.60 | 13.10 | 4.50 | -16.60 | 4.09 |
| Triggs et al., 2010 (2) | RCT | HDRS 24 | 18.00 | 46.70 | 28.20 | 6.00 | 19.80 | 9.10 | -8.40 | 7.33 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|-------------------------|--------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Triggs et al., 2010 (4) | RCT | HDRS 24 | 18.00 | 46.70 | 28.20 | 6.00 | 19.80 | 9.10 | -8.40 | 7.33 |
| Triggs et al., 2010 (1) | RCT | HDRS 24 | 16.00 | 48.50 | 27.20 | 4.80 | 13.70 | 7.60 | -13.50 | 6.11 |
| Triggs et al., 2010 (3) | RCT | HDRS 24 | 16.00 | 48.50 | 27.20 | 4.80 | 13.70 | 7.60 | -13.50 | 6.11 |
| Wang et al., 2017 | RCT | HDRS 24 | 22.00 | 28.82 | 43.50 | 9.89 | 8.41 | 4.02 | -35.09 | 8.16 |
| Zheng et al., 2010 | RCT | HDRS 17 | 19.00 | 26.90 | 24.60 | 3.00 | 13.50 | 5.10 | -11.10 | 4.10 |

Note. HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; NA, not available; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score.

Table 2
Descriptives for tDCS in depression studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|---------------------------|-----------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Brunoni et al., 2013 (2) | RCT | MADRS | 23.00 | 41.20 | 30.80 | 5.80 | 19.10 | 12.20 | -11.70 | 9.91 |
| Brunoni et al., 2013a (1) | crossover | MADRS | 30.00 | 41.00 | 30.73 | 6.72 | 13.17 | 8.46 | -17.56 | 7.00 |
| Brunoni et al., 2014 | RCT | HDRS 21 | 20.00 | 46.10 | 25.60 | 5.80 | 20.00 | 9.80 | -5.60 | 7.87 |
| Brunoni et al., 2017 | RCT | HDRS 17 | 94.00 | 44.60 | 21.80 | 3.90 | 12.80 | 8.10 | -9.00 | 7.10 |
| Loo et al., 2010a | RCT | MADRS | 20.00 | 48.95 | 29.20 | 4.87 | 23.60 | 7.72 | -5.60 | 6.21 |
| Loo et al., 2012 | RCT | MADRS | 31.00 | 47.80 | 30.40 | 6.02 | 20.60 | 7.57 | -9.80 | 6.26 |
| Loo et al., 2018 (1) | RCT | MADRS | 42.00 | 48.93 | 29.00 | 6.48 | 23.00 | 12.96 | -6.00 | 10.48 |
| Palm et al., 2012 (1) | crossover | HDRS 24 | 11.00 | 56.00 | 33.00 | 7.30 | 28.20 | 8.80 | -4.80 | 7.36 |
| Rigonatti et al., 2008 | RCT | BDI | 21.00 | 51.60 | 23.00 | 4.58 | 13.09 | 4.58 | -9.91 | 4.12 |
| Salehinejad et al., 2017 | RCT | HDRS | 12.00 | 26.80 | 24.58 | 2.57 | 12.75 | 3.36 | -11.83 | 2.76 |

Note. HDRS, Hamilton Depression Rating Scale; Hemi, hemisphere; MADRS, Montgomery-Asberg Depression Rating Scale; NA, not available; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score

Table 3
Descriptives for TMS in schizophrenia studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|------------------------------|-----------|----------------|-------|-------|--------|--------|-------|--------|----------|-----------|
| Bais et al., 2014 (2) | RCT | PANSS P3 | 15.00 | 33.90 | 4.60 | 0.63 | 4.33 | 0.90 | -0.27 | 0.73 |
| Bais et al., 2014 (1) | RCT | PANSS P3 | 16.00 | 37.20 | 5.19 | 0.66 | 4.44 | 1.21 | -0.75 | 0.97 |
| Barr et al., 2012 | RCT | PANSS Negative | 13.00 | 40.46 | 14.85 | 6.43 | 15.31 | 9.22 | 0.46 | 7.46 |
| Blumberger et al., 2012a (2) | RCT | PSYRATS | 17.00 | 43.80 | 32.12 | 6.17 | 30.38 | 6.59 | -1.74 | 5.75 |
| Blumberger et al., 2012a (1) | RCT | PSYRATS | 17.00 | 36.60 | 30.82 | 6.56 | 28.47 | 7.48 | -2.35 | 6.36 |
| Dlabac-de Lange et al., 2015 | RCT | SANS | 16.00 | 41.80 | 56.60 | 15.70 | 51.10 | 19.60 | -5.50 | 16.24 |
| Fitzgerald et al., 2008 | RCT | SANS | 12.00 | 37.20 | 55.50 | 4.10 | 38.80 | 11.00 | -16.70 | 9.17 |
| Garg et al., 2016 | RCT | PANSS | 20.00 | 32.40 | 96.30 | 20.36 | 87.60 | 19.60 | -8.70 | 17.97 |
| Hajak et al., 2004 | RCT | PANSS | 10.00 | 37.90 | 82.20 | 15.60 | 68.20 | 17.53 | -14.00 | 8.00 |
| Hoffman et al., 2005 | RCT | HCS | 27.00 | 35.10 | 10.00 | 0.00 | 6.00 | 3.50 | -4.00 | 3.50 |
| Hoffman et al., 2000 | RCT | HCS | 12.00 | 41.80 | 8.50 | 2.20 | 4.80 | 4.39 | -3.70 | 3.80 |
| Hoffman et al., 2003 | RCT | HCS | 12.00 | 35.80 | 10.00 | 0.00 | 4.00 | 2.50 | -6.00 | 2.50 |
| Holi et al., 2004 | RCT | PANSS | 11.00 | 38.50 | 105.20 | 41.20 | 92.30 | 34.30 | -12.90 | 34.49 |
| Jandl et al., 2006 (1) | crossover | PSYRATS | 14.00 | 36.30 | 29.07 | 3.89 | 20.07 | 14.01 | -9.00 | 12.10 |
| Kimura et al., 2016 | RCT | AHRS | 16.00 | 44.60 | 22.90 | 6.80 | 18.40 | 9.70 | -4.50 | 7.86 |
| Klirova et al., 2013 (1) | crossover | AHRS | 14.00 | NA | 24.90 | 5.10 | 18.60 | 4.50 | -6.30 | 4.35 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|--------------------------------|-----------|----------------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Koops et al., 2016 | RCT | AHRS | 37.00 | 38.00 | 24.00 | 5.00 | 22.00 | 6.00 | -2.00 | 5.02 |
| Li et al., 2016 | RCT | SANS | 25.00 | 45.20 | 88.10 | 17.90 | 79.00 | 21.50 | -9.10 | 18.00 |
| Loo et al., 2010 (1) | crossover | AHRS | 18.00 | 33.80 | 22.69 | 6.85 | 21.86 | 4.82 | -0.83 | 5.55 |
| Mcintosh et al., 2004 | crossover | PANSS P3 | 16.00 | 35.90 | 34.30 | 7.70 | 32.60 | 9.10 | -1.70 | 7.65 |
| Paillore-Martinot et al., 2017 | RCT | SAPS | 15.00 | 32.07 | 42.13 | 17.52 | 30.53 | 20.37 | -11.60 | 17.22 |
| Poulet et al., 2004 | crossover | AHRS | 10.00 | 34.90 | 25.90 | 3.60 | 12.85 | 11.38 | -13.05 | 10.80 |
| Prikryl et al., 2013 | RCT | SANS | 23.00 | 31.60 | 68.35 | 14.18 | 39.22 | 21.11 | -29.13 | 17.03 |
| Quan et al., 2015 | RCT | PANSS | 78.00 | 46.87 | 69.38 | 11.64 | 55.27 | 11.74 | -14.11 | 10.51 |
| Rabany et al., 2014 | RCT | SANS | 20.00 | 33.10 | 55.00 | 20.12 | 47.28 | 24.51 | -7.72 | 14.00 |
| Rollnik et al., 2000 | RCT | BPRS | 12.00 | 40.40 | 48.90 | 10.20 | 33.30 | 6.40 | -15.60 | 8.20 |
| Rosa et al., 2007 | RCT | PANSS Positive | 6.00 | 29.83 | 23.67 | 2.42 | 18.50 | 5.82 | -5.17 | 4.79 |
| Saba et al., 2006 | RCT | PANSS | 8.00 | 30.70 | 88.00 | 10.49 | 65.38 | 19.73 | -22.62 | 15.89 |
| Slotema et al., 2011 (2) | RCT | AHRS | 22.00 | 38.00 | 26.00 | 6.60 | 22.70 | 6.40 | -3.30 | 5.85 |
| Slotema et al., 2011 (1) | RCT | AHRS | 20.00 | 36.00 | 26.60 | 6.30 | 22.60 | 7.40 | -4.00 | 6.24 |
| Wobrock et al., 2015 | RCT | PANSS Negative | 76.00 | 36.20 | 25.60 | 4.60 | 22.70 | 6.10 | -2.90 | 4.99 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|-------|--------|-------|---|-----|-------|--------|-------|--------|----------|-----------|
|-------|--------|-------|---|-----|-------|--------|-------|--------|----------|-----------|

Note. AHRS, auditory hallucinations rating scale; BPRS, brief psychiatric rating scale; HCS, hallucination change scale; NA, not available; SANS, scale for the assessment of negative symptoms; SAPS, scale for the assessment of positive symptoms; PSYRATS, psychotic symptom rating scale; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score.

Table 4
Descriptives for tDCS in schizophrenia studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|-----------------------|--------|-------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Brunelin et al., 2012 | RCT | AHRS | 15.00 | 40.40 | 28.30 | 4.10 | 19.90 | 5.80 | -8.40 | 4.70 |
| Frohlich et al., 2016 | RCT | AHRS | 13.00 | 43.38 | 27.00 | 6.90 | 20.62 | 8.13 | -6.38 | 6.84 |
| Mondino et al., 2016 | RCT | AHRS | 11.00 | 36.70 | 27.20 | 4.10 | 19.10 | 7.10 | -8.10 | 5.70 |
| Palm et al., 2016 | RCT | SANS | 10.00 | 38.40 | 59.60 | 23.00 | 38.10 | 21.70 | -21.50 | 20.12 |
| Smith et al., 2015 | RCT | PANSS | 17.00 | 46.76 | 65.14 | 18.38 | 65.71 | 16.96 | 0.57 | 15.93 |

Note. AHRS, auditory hallucinations rating scale; BPRS, brief psychiatric rating scale; HCS, hallucination change scale; Hemi, hemisphere; NA, not available; SANS, scale for the assessment of negative symptoms; SAPS, scale for the assessment of positive symptoms; PSYRATS, psychotic symptom rating scale; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score.

Table 5
Descriptives for TMS in OCD studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|------------------------------|-----------|-------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Elbeh et al., 2016 (2) | RCT | YBOCS | 15.00 | 28.90 | 25.30 | 4.70 | 18.50 | 8.50 | -6.80 | 6.84 |
| Elbeh et al., 2016 (1) | RCT | YBOCS | 15.00 | 26.80 | 26.70 | 6.50 | 14.70 | 5.90 | -12.00 | 5.60 |
| Gomes et al., 2012 | RCT | YBOCS | 12.00 | 35.50 | 36.40 | 3.20 | 21.10 | 3.10 | -15.30 | 2.83 |
| Haghighi et al., 2015 (1) | crossover | YBOCS | 10.00 | 34.90 | 30.40 | 6.54 | 19.10 | 7.74 | -11.30 | 6.51 |
| Hawken et al., 2016 | RCT | YBOCS | 10.00 | 33.00 | 28.00 | 4.74 | 16.90 | 11.04 | -11.10 | 9.05 |
| Jahangard et al., 2016 (1) | crossover | YBOCS | 5.00 | 32.40 | 31.00 | 6.52 | 21.20 | 7.76 | -9.80 | 6.51 |
| Kang et al., 2009 | RCT | YBOCS | 10.00 | 28.60 | 26.50 | 5.64 | 24.20 | 6.71 | -2.30 | 5.63 |
| Mansur et al., 2011 | RCT | YBOCS | 13.00 | 42.10 | 30.00 | 3.84 | 26.75 | 6.28 | -3.25 | 5.04 |
| Mantovani et al., 2010 | RCT | YBOCS | 9.00 | 39.70 | 26.00 | 5.40 | 19.40 | 5.60 | -6.60 | 4.95 |
| Mantovani et al., 2013a | RCT | YBOCS | 9.00 | 39.70 | 26.00 | 5.40 | 19.40 | 5.60 | -6.60 | 4.95 |
| Pelissolo et al., 2016 | RCT | YBOCS | 20.00 | 39.10 | 30.20 | 4.20 | 27.80 | 5.90 | -2.30 | 5.00 |
| Prasko et al., 2006 | RCT | YBOCS | 18.00 | 28.90 | 29.82 | 5.88 | 22.76 | 8.76 | -7.06 | 7.06 |
| Shayganfard et al., 2016 (1) | crossover | YBOCS | 5.00 | 33.80 | 33.00 | 3.08 | 21.80 | 9.31 | -11.20 | 7.87 |

Note. NA, not available; OCD, obsessive-compulsive disorder; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score; YBOCS, Yale-Brown obsessive compulsive scale.

Table 6
Descriptives for TMS in bipolar disorder studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|------------------------------|--------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Dolberg et al., 2002 | RCT | HDRS | 10.00 | 51.80 | 22.00 | 4.80 | 15.70 | 4.80 | -6.30 | 4.31 |
| Fitzgerald et al., 2016 | RCT | HDRS 17 | 23.00 | 46.30 | 23.20 | 4.00 | 19.80 | 5.70 | -3.40 | 4.62 |
| Hernandez-Ribas et al., 2013 | RCT | HDRS | 10.00 | 42.60 | 19.70 | 3.80 | 8.70 | 5.06 | -11.00 | 4.14 |
| Kaptsan et al., 2003 | RCT | BPRS | 11.00 | 43.80 | 35.40 | 9.90 | 25.60 | 5.90 | -9.80 | 7.95 |
| Praharaj et al., 2009 | RCT | YMRS | 21.00 | 29.76 | 20.85 | 5.21 | 5.76 | 3.26 | -15.09 | 4.19 |
| Tavares et al., 2017 | RCT | HDRS 17 | 25.00 | 43.50 | 25.80 | 5.25 | 14.08 | 8.99 | -11.72 | 7.22 |

Note. BPRS, Brief psychiatric rating scale; HDRS, Hamilton Depression Rating Scale; NA, not available; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score; YMRS, Young Mania Rating Scale.

Table 7
Descriptives for tDCS in bipolar disorder studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|----------------------|--------|-------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Loo et al., 2018 (2) | RCT | MADRS | 19.00 | 49.11 | 31.50 | 4.36 | 24.00 | 8.72 | -7.50 | 7.05 |

Note. BPRS, Brief psychiatric rating scale; HDRS, Hamilton Depression Rating Scale; Hemi, hemisphere; NA, not available; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score; YMRS, Young Mania Rating Scale.

Table 8
Descriptives for TMS in depression studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|-----------------------------|-----------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Anderson et al., 2007 | RCT | MADRS | 13.00 | 48.00 | 26.70 | 3.60 | 15.00 | 9.70 | -11.70 | 8.08 |
| Avery et al., 2006 | RCT | HDRS 17 | 35.00 | 44.30 | 23.50 | 3.90 | 15.70 | 8.72 | -7.80 | 7.80 |
| Baeken et al., 2013 (1) | crossover | HDRS 17 | 9.00 | 51.78 | 26.33 | 8.15 | 19.63 | 8.35 | -6.70 | 7.42 |
| Baeken et al., 2015 (1) | crossover | HDRS | 9.00 | 50.78 | 25.44 | 6.79 | 17.89 | 6.79 | -7.55 | 6.10 |
| Benadhira et al., 2017 | RCT | HDRS 17 | 10.00 | 51.80 | 9.10 | 4.65 | 8.50 | 4.01 | -0.60 | 3.93 |
| Berman et al., 2000 | RCT | HDRS 25 | 10.00 | 45.20 | 37.10 | 9.20 | 23.10 | 14.89 | -14.00 | 11.70 |
| Blumberger et al., 2012 (1) | RCT | HDRS 17 | 22.00 | 48.90 | 26.00 | 3.30 | 19.60 | 5.60 | -6.40 | 4.50 |
| Blumberger et al., 2012 (2) | RCT | HDRS 17 | 26.00 | 58.00 | 25.10 | 3.80 | 15.30 | 6.70 | -9.80 | 5.38 |
| Blumberger et al., 2016 (2) | RCT | HDRS 17 | 40.00 | 46.50 | 26.00 | 3.40 | 19.60 | 7.78 | -6.40 | 7.00 |
| Blumberger et al., 2016 (1) | RCT | HDRS 17 | 40.00 | 46.40 | 24.10 | 3.20 | 17.30 | 7.88 | -6.80 | 7.20 |
| Bortolomasi et al., 2007 | RCT | HAMD 24 | 12.00 | NA | 25.17 | 7.80 | 11.33 | 9.00 | -13.84 | 7.63 |
| Boutros et al., 2002 | RCT | HDRS | 12.00 | 49.50 | 34.40 | 10.10 | 27.10 | 13.20 | -7.30 | 10.83 |
| Bretlau et al., 2008 | RCT | HDRS | 22.00 | 53.10 | 25.30 | 3.00 | 16.40 | 4.50 | -8.90 | 3.63 |
| Carpenter et al., 2017 | RCT | HDRS 24 | 47.00 | 45.60 | 31.30 | 5.50 | 16.20 | 11.06 | -15.10 | 9.60 |
| Carretero et al., 2009 | RCT | HDRS 17 | 14.00 | 47.50 | 19.40 | 5.40 | 15.60 | 3.80 | -3.80 | 4.38 |
| Fitzgerald et al., 2003 (1) | crossover | MADRS | 20.00 | 42.20 | 36.05 | 7.55 | 30.80 | 7.50 | -5.25 | 6.76 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|-----------------------------|-----------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Fitzgerald et al., 2006 | RCT | MADRS | 25.00 | 46.80 | 34.00 | 5.90 | 26.20 | 10.20 | -7.80 | 8.19 |
| Fitzgerald et al., 2012 (2) | RCT | HDRS 17 | 22.00 | 40.45 | 24.30 | 3.60 | 22.20 | 6.00 | -2.10 | 4.82 |
| Fitzgerald et al., 2012 (1) | RCT | HDRS 17 | 24.00 | 43.40 | 23.70 | 3.80 | 19.60 | 4.20 | -4.10 | 3.61 |
| Garcia-Toro et al., 2001 | RCT | HDRS 21 | 17.00 | 51.50 | 27.11 | 6.65 | 20.06 | 8.73 | -7.05 | 5.66 |
| Garcia-Toro et al., 2001a | RCT | HDRS 21 | 11.00 | 43.20 | 25.90 | 6.40 | 16.10 | 7.70 | -9.80 | 6.44 |
| George et al., 1997 (1) | crossover | HDRS 21 | 7.00 | 42.43 | 30.00 | 4.00 | 23.00 | 9.00 | -7.00 | 7.35 |
| George et al., 2000 (1) | RCT | HDRS 21 | 10.00 | 42.60 | 30.00 | 5.80 | 22.20 | 10.60 | -7.80 | 8.53 |
| George et al., 2000 (2) | RCT | HDRS 21 | 10.00 | 42.20 | 26.30 | 5.90 | 13.50 | 5.80 | -12.80 | 5.26 |
| George et al., 2010 | RCT | HDRS | 92.00 | 47.70 | 26.26 | 4.95 | 21.61 | 9.26 | -4.65 | 7.46 |
| Hausmann et al., 2004 | RCT | HDRS 21 | 25.00 | 46.28 | 32.30 | 5.90 | 17.60 | 9.00 | -14.70 | 7.25 |
| Holtzheimer et al., 2004 | RCT | HDRS 17 | 7.00 | 40.40 | 22.70 | 5.30 | 14.60 | 3.20 | -8.10 | 4.26 |
| Hoppner et al., 2003 (2) | RCT | HDRS 21 | 10.00 | 52.00 | 22.80 | 4.70 | 16.50 | 7.00 | -6.30 | 5.65 |
| Hoppner et al., 2003 (1) | RCT | HDRS 21 | 10.00 | 60.36 | 22.50 | 4.50 | 14.50 | 6.00 | -8.00 | 4.91 |
| Huang et al., 2012 | RCT | HDRS 17 | 28.00 | 32.77 | 22.71 | 2.27 | 15.36 | 1.73 | -7.35 | 1.86 |
| Januel et al., 2006 | RCT | HDRS 17 | 11.00 | 38.64 | 21.73 | 3.52 | 9.90 | 5.95 | -11.83 | 4.78 |
| Kang et al., 2016 | RCT | HDRS 17 | 12.00 | 42.80 | 24.10 | 6.40 | 10.10 | 3.80 | -14.00 | 5.14 |
| Klein et al., 1999 | RCT | HDRS 17 | 36.00 | 60.50 | 25.80 | 5.60 | 13.70 | 9.20 | -12.10 | 7.39 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|------------------------------------|--------|---------------|--------|-------|-------|--------|-------|--------|----------|-----------|
| Koerselman et al., 2004 | RCT | HDRS 17 | 26.00 | 51.00 | 25.90 | 4.33 | 21.10 | 7.47 | -4.80 | 6.00 |
| Kreuzer et al., 2012 | RCT | HDRS modified | 21.00 | 45.30 | 21.43 | 5.30 | 8.74 | 6.10 | -12.69 | 5.17 |
| Krstic et al., 2014 | RCT | HDRS 24 | 11.00 | 50.70 | 30.09 | 3.53 | 16.73 | 5.71 | -13.36 | 4.59 |
| Leuchter et al., 2015 | RCT | HDRS 17 | 59.00 | 46.70 | 21.78 | 3.79 | 12.78 | 5.90 | -9.00 | 4.75 |
| Manes et al., 2001 | RCT | HDRS | 10.00 | 60.50 | 22.70 | 5.20 | 13.70 | 5.40 | -9.00 | 4.77 |
| Mantovani et al., 2013 | RCT | HDRS 24 | 12.00 | 40.20 | 31.90 | 6.50 | 25.30 | 9.80 | -6.60 | 7.90 |
| Mogg et al., 2008 | RCT | HDRS 17 | 29.00 | 55.00 | 20.50 | 4.40 | 16.00 | 8.24 | -4.50 | 6.64 |
| Moller et al., 2006 | RCT | HDRS 17 | 10.00 | 54.00 | 22.10 | 7.00 | 13.80 | 7.00 | -8.30 | 6.29 |
| Mosimann et al., 2004 | RCT | HDRS 21 | 15.00 | 60.00 | 28.50 | 4.60 | 23.30 | 7.20 | -5.20 | 5.79 |
| Nongpiur et al., 2011 | RCT | HDRS 21 | 18.00 | 33.28 | 29.00 | 5.97 | 8.56 | 4.68 | -20.44 | 4.92 |
| O'Reardon et al., 2007 | RCT | MADRS | 155.00 | 47.90 | 32.80 | 6.00 | 27.00 | 11.10 | -5.80 | 8.93 |
| Padberg et al., 1999 (1) | RCT | HDRS | 6.00 | 63.50 | 30.20 | 9.50 | 28.50 | 9.40 | -1.70 | 8.50 |
| Padberg et al., 1999 (2) | RCT | HDRS | 6.00 | 46.70 | 26.70 | 9.40 | 21.50 | 21.50 | -5.20 | 17.60 |
| Paillere-Martinot et al., 2010 (3) | RCT | MADRS | 7.00 | NA | 34.70 | 6.00 | 23.30 | 14.50 | -11.40 | 13.20 |
| Paillere-Martinot et al., 2010 (1) | RCT | MADRS | 18.00 | 48.19 | 32.00 | 7.78 | 17.30 | 11.82 | -14.70 | 8.90 |
| Paillere-Martinot et al., 2010 (2) | RCT | MADRS | 9.00 | NA | 34.00 | 8.50 | 13.70 | 15.37 | -20.30 | 12.80 |
| Pallanti et al., 2010 (1) | RCT | HDRS | 20.00 | 47.60 | 28.75 | 6.01 | 22.00 | 6.71 | -6.75 | 5.75 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|------------------------------|-----------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Pallanti et al., 2010 (2) | RCT | HDRS | 20.00 | 51.20 | 27.95 | 5.89 | 16.00 | 7.60 | -11.95 | 6.25 |
| Pascual-Leone et al., 1996 | crossover | HDRS 21 | 17.00 | 48.60 | 25.20 | 13.50 | 13.80 | 14.00 | -11.40 | 12.37 |
| Ray et al., 2011 | RCT | HDRS | 20.00 | 36.75 | 29.60 | 3.79 | 4.50 | 5.23 | -25.10 | 4.25 |
| Rossini et al., 2005 | RCT | HDRS 24 | 50.00 | 48.40 | 25.10 | 3.50 | 13.01 | 8.08 | -12.09 | 7.28 |
| Rumi et al., 2005 | RCT | HDRS 17 | 22.00 | 39.30 | 29.71 | 6.38 | 13.00 | 6.38 | -16.71 | 5.74 |
| Speer et al., 2014 (1) | RCT | HDRS 28 | 8.00 | 41.30 | 35.80 | 10.60 | 32.50 | 10.10 | -3.30 | 9.31 |
| Speer et al., 2014 (2) | RCT | HDRS 28 | 8.00 | 39.60 | 28.60 | 7.60 | 25.10 | 6.90 | -3.50 | 6.55 |
| Stern et al., 2007 (2) | RCT | HDRS 21 | 10.00 | 52.30 | 27.60 | 3.90 | 27.60 | 5.90 | 0.00 | 4.75 |
| Stern et al., 2007 (3) | RCT | HDRS 21 | 10.00 | 52.80 | 27.90 | 3.80 | 15.80 | 4.80 | -12.10 | 3.97 |
| Stern et al., 2007 (1) | RCT | HDRS 21 | 10.00 | 53.20 | 27.80 | 3.20 | 15.10 | 6.00 | -12.70 | 4.83 |
| Su et al., 2005 (1) | RCT | HDRS 21 | 10.00 | 43.60 | 23.20 | 7.50 | 9.80 | 7.10 | -13.40 | 6.57 |
| Su et al., 2005 (2) | RCT | HDRS 21 | 10.00 | 43.20 | 26.50 | 5.20 | 12.30 | 7.70 | -14.20 | 6.21 |
| Theleiteris et al., 2017 (1) | RCT | HDRS 17 | 26.00 | 39.10 | 30.60 | 3.20 | 15.60 | 3.70 | -15.00 | 3.13 |
| Theleiteris et al., 2017 (3) | RCT | HDRS 17 | 26.00 | 39.10 | 30.60 | 3.20 | 15.60 | 3.70 | -15.00 | 3.13 |
| Theleiteris et al., 2017 (2) | RCT | HDRS 17 | 26.00 | 38.90 | 29.70 | 4.60 | 13.10 | 4.50 | -16.60 | 4.09 |
| Theleiteris et al., 2017 (4) | RCT | HDRS 17 | 26.00 | 38.90 | 29.70 | 4.60 | 13.10 | 4.50 | -16.60 | 4.09 |
| Triggs et al., 2010 (2) | RCT | HDRS 24 | 18.00 | 46.70 | 28.20 | 6.00 | 19.80 | 9.10 | -8.40 | 7.33 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|-------------------------|--------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Triggs et al., 2010 (4) | RCT | HDRS 24 | 18.00 | 46.70 | 28.20 | 6.00 | 19.80 | 9.10 | -8.40 | 7.33 |
| Triggs et al., 2010 (1) | RCT | HDRS 24 | 16.00 | 48.50 | 27.20 | 4.80 | 13.70 | 7.60 | -13.50 | 6.11 |
| Triggs et al., 2010 (3) | RCT | HDRS 24 | 16.00 | 48.50 | 27.20 | 4.80 | 13.70 | 7.60 | -13.50 | 6.11 |
| Wang et al., 2017 | RCT | HDRS 24 | 22.00 | 28.82 | 43.50 | 9.89 | 8.41 | 4.02 | -35.09 | 8.16 |
| Zheng et al., 2010 | RCT | HDRS 17 | 19.00 | 26.90 | 24.60 | 3.00 | 13.50 | 5.10 | -11.10 | 4.10 |

Note. HDRS, Hamilton Depression Rating Scale; MADRS, Montgomery-Asberg Depression Rating Scale; NA, not available; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score.

Table 9
Descriptives for tDCS in depression studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|---------------------------|-----------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Brunoni et al., 2013 (2) | RCT | MADRS | 23.00 | 41.20 | 30.80 | 5.80 | 19.10 | 12.20 | -11.70 | 9.91 |
| Brunoni et al., 2013a (1) | crossover | MADRS | 30.00 | 41.00 | 30.73 | 6.72 | 13.17 | 8.46 | -17.56 | 7.00 |
| Brunoni et al., 2014 | RCT | HDRS 21 | 20.00 | 46.10 | 25.60 | 5.80 | 20.00 | 9.80 | -5.60 | 7.87 |
| Brunoni et al., 2017 | RCT | HDRS 17 | 94.00 | 44.60 | 21.80 | 3.90 | 12.80 | 8.10 | -9.00 | 7.10 |
| Loo et al., 2010a | RCT | MADRS | 20.00 | 48.95 | 29.20 | 4.87 | 23.60 | 7.72 | -5.60 | 6.21 |
| Loo et al., 2012 | RCT | MADRS | 31.00 | 47.80 | 30.40 | 6.02 | 20.60 | 7.57 | -9.80 | 6.26 |
| Loo et al., 2018 (1) | RCT | MADRS | 42.00 | 48.93 | 29.00 | 6.48 | 23.00 | 12.96 | -6.00 | 10.48 |
| Palm et al., 2012 (1) | crossover | HDRS 24 | 11.00 | 56.00 | 33.00 | 7.30 | 28.20 | 8.80 | -4.80 | 7.36 |
| Rigonatti et al., 2008 | RCT | BDI | 21.00 | 51.60 | 23.00 | 4.58 | 13.09 | 4.58 | -9.91 | 4.12 |
| Salehinejad et al., 2017 | RCT | HDRS | 12.00 | 26.80 | 24.58 | 2.57 | 12.75 | 3.36 | -11.83 | 2.76 |

Note. HDRS, Hamilton Depression Rating Scale; Hemi, hemisphere; MADRS, Montgomery-Asberg Depression Rating Scale; NA, not available; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score

Table 10
Descriptives for TMS in schizophrenia studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|------------------------------|-----------|----------------|-------|-------|--------|--------|-------|--------|----------|-----------|
| Bais et al., 2014 (2) | RCT | PANSS P3 | 15.00 | 33.90 | 4.60 | 0.63 | 4.33 | 0.90 | -0.27 | 0.73 |
| Bais et al., 2014 (1) | RCT | PANSS P3 | 16.00 | 37.20 | 5.19 | 0.66 | 4.44 | 1.21 | -0.75 | 0.97 |
| Barr et al., 2012 | RCT | PANSS Negative | 13.00 | 40.46 | 14.85 | 6.43 | 15.31 | 9.22 | 0.46 | 7.46 |
| Blumberger et al., 2012a (2) | RCT | PSYRATS | 17.00 | 43.80 | 32.12 | 6.17 | 30.38 | 6.59 | -1.74 | 5.75 |
| Blumberger et al., 2012a (1) | RCT | PSYRATS | 17.00 | 36.60 | 30.82 | 6.56 | 28.47 | 7.48 | -2.35 | 6.36 |
| Dlabac-de Lange et al., 2015 | RCT | SANS | 16.00 | 41.80 | 56.60 | 15.70 | 51.10 | 19.60 | -5.50 | 16.24 |
| Fitzgerald et al., 2008 | RCT | SANS | 12.00 | 37.20 | 55.50 | 4.10 | 38.80 | 11.00 | -16.70 | 9.17 |
| Garg et al., 2016 | RCT | PANSS | 20.00 | 32.40 | 96.30 | 20.36 | 87.60 | 19.60 | -8.70 | 17.97 |
| Hajak et al., 2004 | RCT | PANSS | 10.00 | 37.90 | 82.20 | 15.60 | 68.20 | 17.53 | -14.00 | 8.00 |
| Hoffman et al., 2005 | RCT | HCS | 27.00 | 35.10 | 10.00 | 0.00 | 6.00 | 3.50 | -4.00 | 3.50 |
| Hoffman et al., 2000 | RCT | HCS | 12.00 | 41.80 | 8.50 | 2.20 | 4.80 | 4.39 | -3.70 | 3.80 |
| Hoffman et al., 2003 | RCT | HCS | 12.00 | 35.80 | 10.00 | 0.00 | 4.00 | 2.50 | -6.00 | 2.50 |
| Holi et al., 2004 | RCT | PANSS | 11.00 | 38.50 | 105.20 | 41.20 | 92.30 | 34.30 | -12.90 | 34.49 |
| Jandl et al., 2006 (1) | crossover | PSYRATS | 14.00 | 36.30 | 29.07 | 3.89 | 20.07 | 14.01 | -9.00 | 12.10 |
| Kimura et al., 2016 | RCT | AHRS | 16.00 | 44.60 | 22.90 | 6.80 | 18.40 | 9.70 | -4.50 | 7.86 |
| Klirova et al., 2013 (1) | crossover | AHRS | 14.00 | NA | 24.90 | 5.10 | 18.60 | 4.50 | -6.30 | 4.35 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|--------------------------------|-----------|----------------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Koops et al., 2016 | RCT | AHRS | 37.00 | 38.00 | 24.00 | 5.00 | 22.00 | 6.00 | -2.00 | 5.02 |
| Li et al., 2016 | RCT | SANS | 25.00 | 45.20 | 88.10 | 17.90 | 79.00 | 21.50 | -9.10 | 18.00 |
| Loo et al., 2010 (1) | crossover | AHRS | 18.00 | 33.80 | 22.69 | 6.85 | 21.86 | 4.82 | -0.83 | 5.55 |
| Mcintosh et al., 2004 | crossover | PANSS P3 | 16.00 | 35.90 | 34.30 | 7.70 | 32.60 | 9.10 | -1.70 | 7.65 |
| Paillore-Martinot et al., 2017 | RCT | SAPS | 15.00 | 32.07 | 42.13 | 17.52 | 30.53 | 20.37 | -11.60 | 17.22 |
| Poulet et al., 2004 | crossover | AHRS | 10.00 | 34.90 | 25.90 | 3.60 | 12.85 | 11.38 | -13.05 | 10.80 |
| Prikryl et al., 2013 | RCT | SANS | 23.00 | 31.60 | 68.35 | 14.18 | 39.22 | 21.11 | -29.13 | 17.03 |
| Quan et al., 2015 | RCT | PANSS | 78.00 | 46.87 | 69.38 | 11.64 | 55.27 | 11.74 | -14.11 | 10.51 |
| Rabany et al., 2014 | RCT | SANS | 20.00 | 33.10 | 55.00 | 20.12 | 47.28 | 24.51 | -7.72 | 14.00 |
| Rollnik et al., 2000 | RCT | BPRS | 12.00 | 40.40 | 48.90 | 10.20 | 33.30 | 6.40 | -15.60 | 8.20 |
| Rosa et al., 2007 | RCT | PANSS Positive | 6.00 | 29.83 | 23.67 | 2.42 | 18.50 | 5.82 | -5.17 | 4.79 |
| Saba et al., 2006 | RCT | PANSS | 8.00 | 30.70 | 88.00 | 10.49 | 65.38 | 19.73 | -22.62 | 15.89 |
| Slotema et al., 2011 (2) | RCT | AHRS | 22.00 | 38.00 | 26.00 | 6.60 | 22.70 | 6.40 | -3.30 | 5.85 |
| Slotema et al., 2011 (1) | RCT | AHRS | 20.00 | 36.00 | 26.60 | 6.30 | 22.60 | 7.40 | -4.00 | 6.24 |
| Wobrock et al., 2015 | RCT | PANSS Negative | 76.00 | 36.20 | 25.60 | 4.60 | 22.70 | 6.10 | -2.90 | 4.99 |

Table 14 continued

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|-------|--------|-------|---|-----|-------|--------|-------|--------|----------|-----------|
|-------|--------|-------|---|-----|-------|--------|-------|--------|----------|-----------|

Note. AHRS, auditory hallucinations rating scale; BPRS, brief psychiatric rating scale; HCS, hallucination change scale; NA, not available; SANS, scale for the assessment of negative symptoms; SAPS, scale for the assessment of positive symptoms; PSYRATS, psychotic symptom rating scale; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score.

Table 11
Descriptives for tDCS in schizophrenia studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|-----------------------|--------|-------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Brunelin et al., 2012 | RCT | AHRS | 15.00 | 40.40 | 28.30 | 4.10 | 19.90 | 5.80 | -8.40 | 4.70 |
| Frohlich et al., 2016 | RCT | AHRS | 13.00 | 43.38 | 27.00 | 6.90 | 20.62 | 8.13 | -6.38 | 6.84 |
| Mondino et al., 2016 | RCT | AHRS | 11.00 | 36.70 | 27.20 | 4.10 | 19.10 | 7.10 | -8.10 | 5.70 |
| Palm et al., 2016 | RCT | SANS | 10.00 | 38.40 | 59.60 | 23.00 | 38.10 | 21.70 | -21.50 | 20.12 |
| Smith et al., 2015 | RCT | PANSS | 17.00 | 46.76 | 65.14 | 18.38 | 65.71 | 16.96 | 0.57 | 15.93 |

Note. AHRS, auditory hallucinations rating scale; BPRS, brief psychiatric rating scale; HCS, hallucination change scale; Hemi, hemisphere; NA, not available; SANS, scale for the assessment of negative symptoms; SAPS, scale for the assessment of positive symptoms; PSYRATS, psychotic symptom rating scale; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score.

Table 12
Descriptives for TMS in OCD studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|------------------------------|-----------|-------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Elbeh et al., 2016 (2) | RCT | YBOCS | 15.00 | 28.90 | 25.30 | 4.70 | 18.50 | 8.50 | -6.80 | 6.84 |
| Elbeh et al., 2016 (1) | RCT | YBOCS | 15.00 | 26.80 | 26.70 | 6.50 | 14.70 | 5.90 | -12.00 | 5.60 |
| Gomes et al., 2012 | RCT | YBOCS | 12.00 | 35.50 | 36.40 | 3.20 | 21.10 | 3.10 | -15.30 | 2.83 |
| Haghighi et al., 2015 (1) | crossover | YBOCS | 10.00 | 34.90 | 30.40 | 6.54 | 19.10 | 7.74 | -11.30 | 6.51 |
| Hawken et al., 2016 | RCT | YBOCS | 10.00 | 33.00 | 28.00 | 4.74 | 16.90 | 11.04 | -11.10 | 9.05 |
| Jahangard et al., 2016 (1) | crossover | YBOCS | 5.00 | 32.40 | 31.00 | 6.52 | 21.20 | 7.76 | -9.80 | 6.51 |
| Kang et al., 2009 | RCT | YBOCS | 10.00 | 28.60 | 26.50 | 5.64 | 24.20 | 6.71 | -2.30 | 5.63 |
| Mansur et al., 2011 | RCT | YBOCS | 13.00 | 42.10 | 30.00 | 3.84 | 26.75 | 6.28 | -3.25 | 5.04 |
| Mantovani et al., 2010 | RCT | YBOCS | 9.00 | 39.70 | 26.00 | 5.40 | 19.40 | 5.60 | -6.60 | 4.95 |
| Mantovani et al., 2013a | RCT | YBOCS | 9.00 | 39.70 | 26.00 | 5.40 | 19.40 | 5.60 | -6.60 | 4.95 |
| Pelissolo et al., 2016 | RCT | YBOCS | 20.00 | 39.10 | 30.20 | 4.20 | 27.80 | 5.90 | -2.30 | 5.00 |
| Prasko et al., 2006 | RCT | YBOCS | 18.00 | 28.90 | 29.82 | 5.88 | 22.76 | 8.76 | -7.06 | 7.06 |
| Shayganfard et al., 2016 (1) | crossover | YBOCS | 5.00 | 33.80 | 33.00 | 3.08 | 21.80 | 9.31 | -11.20 | 7.87 |

Note. NA, not available; OCD, obsessive-compulsive disorder; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score; YBOCS, Yale-Brown obsessive compulsive scale.

Table 13
Descriptives for TMS in bipolar disorder studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|------------------------------|--------|---------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Dolberg et al., 2002 | RCT | HDRS | 10.00 | 51.80 | 22.00 | 4.80 | 15.70 | 4.80 | -6.30 | 4.31 |
| Fitzgerald et al., 2016 | RCT | HDRS 17 | 23.00 | 46.30 | 23.20 | 4.00 | 19.80 | 5.70 | -3.40 | 4.62 |
| Hernandez-Ribas et al., 2013 | RCT | HDRS | 10.00 | 42.60 | 19.70 | 3.80 | 8.70 | 5.06 | -11.00 | 4.14 |
| Kaptsan et al., 2003 | RCT | BPRS | 11.00 | 43.80 | 35.40 | 9.90 | 25.60 | 5.90 | -9.80 | 7.95 |
| Praharaj et al., 2009 | RCT | YMRS | 21.00 | 29.76 | 20.85 | 5.21 | 5.76 | 3.26 | -15.09 | 4.19 |
| Tavares et al., 2017 | RCT | HDRS 17 | 25.00 | 43.50 | 25.80 | 5.25 | 14.08 | 8.99 | -11.72 | 7.22 |

Note. BPRS, Brief psychiatric rating scale; HDRS, Hamilton Depression Rating Scale; NA, not available; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score; YMRS, Young Mania Rating Scale.

Table 14
Descriptives for tDCS in bipolar disorder studies.

| Study | Design | Scale | N | Age | t0(M) | t0(SD) | t1(M) | t1(SD) | t1-t0(M) | t1-t0(SD) |
|----------------------|--------|-------|-------|-------|-------|--------|-------|--------|----------|-----------|
| Loo et al., 2018 (2) | RCT | MADRS | 19.00 | 49.11 | 31.50 | 4.36 | 24.00 | 8.72 | -7.50 | 7.05 |

Note. BPRS, Brief psychiatric rating scale; HDRS, Hamilton Depression Rating Scale; Hemi, hemisphere; NA, not available; RCT, randomized controlled trial; t0, baseline; t1, outcome; t1-t0, pre-post difference score; YMRS, Young Mania Rating Scale.

Conflict of interest

SW, PH, WM, NM, and AJ report no conflicts of interest.

Funding/Support

The study had no funder or financial supporter.

References

1. Moher, D. *et al.* Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015 statement. *Systematic reviews* **4**, 1 (2015).
2. Higgins, J. P. & Green, S. *Cochrane handbook for systematic reviews of interventions*. vol. 4 (John Wiley & Sons, 2011).
3. Harrer, M., Cuijpers, P., Furukawa, T. & Ebert, D. D. *Dmetar: Companion r package for the guide 'doing meta-analysis in r*. (R package version 0.0.9000, 2019).
4. Nakagawa, S. *et al.* Meta-analysis of variation: Ecological and evolutionary applications and beyond. *Methods Ecol Evol* **6**, 143–152 (2015).
5. Mills, H. L. *et al.* Detecting heterogeneity of intervention effects using analysis and meta-analysis of differences in variance between arms of a trial. *medRxiv* (2020) doi:10.1101/2020.03.07.20032516.